Anemia is common in congestive heart failure (CHF) and is associated with an increased mortality and morbidity. The most likely causes of anemia are chronic kidney disease (CKD) and excessive cytokine production, both of which can cause depression of erythropoietin (EPO) production and bone marrow activity. The cytokines also induce iron deficiency by both reducing gastrointestinal iron absorption and iron release from iron stores located in the macrophages and hepatocytes. Iron deficiency can cause thrombocytosis which might also contribute to cardiovascular complications in both CHF and CKD and is partially reversible with iron treatment. Thus attempts to control this anemia will have to consider both the use of erythropoiesis-stimulating agents (ESA), such as EPO, as well as oral and, probably more importantly, intravenous (IV) iron. The many studies on anemia in CHF patients treated with ESA and oral or IV iron, and even with IV iron without ESA have up to now shown a quite consistent positive effect on hospitalization, fatigue, shortness of breath, quality of life, exercise capacity, and β-natriuretic peptide reduction, in the absence of increased cardiovascular damage related to the therapy. Adequately powered long-term placebo-controlled studies of ESA and/or IV iron are currently being carried out and their results are eagerly awaited.

Keywords:
Anemia, Chronic kidney disease, Congestive heart failure, Dialysis, Erythropoietin, Iron, Renal failure
1.
Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, Ford E, Furie K, Go A, Greenlund K, Haase N, Hailpern S, Ho M, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott M, Meigs J, Mozaffarian D, Nichol G, O‘Donnell C, Roger V, Rosamond W, Sacco R, Sorlie P, Stafford R, Steinberger J, Thom T, Wasserthiel-Smoller S, Wong N, Wylie-Rosett J, Hong Y, American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics – 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:480–486.
2.
Bleumink GS, Knetsch AM, Sturkenboom MC, Straus SM, Hofman A, Deckers JW, Witteman JC, Stricker BH: Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure. The Rotterdam Study. Eur Heart J 2004;25:1614–1619.
3.
Beutler E, Waalen J: The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration. Blood 2006;107:1747–1750.
4.
Silverberg DS, Wexler D, Iaina A, Schwartz D: The role of anaemia in patients with congestive heart failure: a short review. Eur J Heart Failure 2008;10:819–823.
5.
Anand IS: Anemia and chronic heart failure. J Am Coll Cardiol 2008;52:501–511.
6.
Mitchell JE: Emerging role of anemia in heart failure. Am J Cardiol 2007;99:15D–20D.
7.
Silverberg DS, Wexler D, Iaina A, Schwartz D: The interaction between heart failure and other heart disease and anemia. Semin Nephrol 2006;26:296–306.
8.
Tang YD, Katz SD: Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 2006;113:2454–2461.
9.
Kazory A, Ross EA: Anemia: the point of convergence or divergence for kidney disease and heart failure? J Am Coll Cardiol 2009;53:639–647.
10.
Groenwald HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, van der Meer P: Anemia and mortality in heart failure patients: a systematic review and meta-analysis. J Am Coll Cardiol 2008;52:818–827.
11.
Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM: Secular trends in renal dysfunction in hospitalized heart failure patients. J Card Fail 2006;12:257–262.
12.
Dunlay SD, Weston SA, Redfield MM, Killian JM, Roger VL: Anemia and heart failure: a community study. Am J Med 2008;121:726–732.
13.
Bansal N, Tighiouart H, Weiner D, Griffith J, Vlagopoulos P, Salem D, Levin A, Sarnak MJ: Anemia as a risk factor for kidney function decline in individuals with heart failure. Am J Cardiol 2007;99:1137–1142.
14.
Nemeth E: Iron regulation and erythropoiesis. Curr Opin Hematol 2008;15:169–175.
15.
Weiss G: Iron metabolism in the anemia of chronic disease. Biochim Biophys Acta 2009;1790:682–693.
16.
Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, Taube DH, Bloom SR, Tam FW, Chapman RS, Maxwell PH, Choi P: Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 2009;75:976–981.
17.
Lopez-Gomez JM, Portoles JM, Aljama P: Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney Int 2008;74(suppl 11):S75–S81.
18.
Weiss G, Meusburger E, Radacher G, Garimorth K, Neyer U, Mayer G: Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int 2003;64:572–578.
19.
Androne AS, Katz SD, Lund L, LaManca J, Hudaihed A, Hryniewicz K, Mancini DM: Hemodilution is common in patients with advanced heart failure. Circulation 2003;107:226–229.
20.
Westenbrink BD, Visser FW, Voors AA, Smilde TD, Lipsic E, Navis G, Hillege HL, van Gilst WH, van Veldhuisen DJ: Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well. Eur Heart J 2007;28:166–171.
21.
Adlbrecht C, Kommata S, Hulsmann M, Szekeres T, Bieglmayer C, Strunk G, Karanikas G, Berger R, Mörtl D, Kletter K, Maurer G, Lang IM, Pacher R: Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body’s red cell volume. Eur Heart J 2008;29:2343–2350.
22.
Abramov D, Cohen RS, Katz SD, Mancini D, Maurer MS: Comparison of blood volume characteristics in anemic patients with low versus preserved left ventricular ejection fraction. Am J Cardiol 2008;102:1069–1072.
23.
Hutchinson C, Geissler CA, Powell JJ, Bomford A: Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut 2007;56:1291–1295.
24.
Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, Brosh D, Laniado S, Schwartz D, Yachnin T, Shapira I, Gavish D, Baruch R, Koifman B, Kaplan C, Steinbruch S, Iaina A: The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000;35:1737–1744.
25.
Silverberg DS, Wexler D, Blum M, Tchebiner JZ, Sheps D, Keren G, Schwartz D, Baruch R, Yachnin T, Shaked M, Schwartz I, Steinbruch S, Iaina A: The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 2003;18:141–146.
26.
Silverberg DS, Wexler D, Blum M, Iaina A, Sheps D, Keren G, Scherhag A, Schwartz D: Effects of treatment with epoetin beta on outcomes in patients with anaemia and chronic heart failure. Kidney Blood Press Res 2005;28:41–47.
27.
Hampl H, Hennig L, Rosenberger C, Gogoli L, Riedel E, Scherhag A: Optimized heart failure therapy and complete anemia correction on left ventricular hypertrophy in non-diabetic and diabetic patients undergoing hemodialysis. Kidney Blood Press Res 2005;28:353–362.
28.
Hampl H, Hennig L, Rosenberger C, Amirkhalily M, Gogoll L, Riedel E, Scherhag A: Effects of optimized heart failure therapy and anemia correction with epoetin β on left ventricular mass in hemodialysis patients. Am J Nephrol 2005;25:211–220.
29.
Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, Schwartz D, Yachnin T, Steinbruch S, Shapira I, Laniado S, Iaina A: The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001;37:1775–1780.
30.
Pappas KD, Gouva CD, Katopodis KP, Nikolopoulos PM, Korantzopoulos PG, Michalis LK, Goudevenos JA, Siamopoulos KC: Correction of anemia with erythropoietin in chronic kidney disease (stage 3 and 4): effects on cardiac performance. Cardiovasc Drugs Ther 2008;22:37–44.
31.
Cosyns B, Velez-Roa S, Droogmans S, Pierard LA, Lancellotti P: Effects of erythropoietin administration on mitral regurgitation and left ventricular remodeling in heart failure patients. Int J Cardiol, E-pub ahead of print.
32.
Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS: Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003;107:294–299.
33.
Kourea K, Parissis JT, Farmakis D, Panou F, Paraskevaidis I, Venetsanou K, Filippatos G, Kremastinos DT: Effects of darbepoetin-alfa on plasma pro-inflammatory cytokines, anti-inflammatory cytokine interleukin-10 and soluble Fas/Fas ligand system in anemic patients with chronic heart failure. Atherosclerosis 2008;199:215–221.
34.
Parissis JT, Kourea K, Panou F, Farmakis D, Paraskevaidis I, Ikonomidis I, Filippatos G, Kremastinos DT: Effects of darbepoetin α on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am Heart J 2008;155:751.e1–e7.
35.
Kourea K, Parissis JT, Farmakis D, Paraskevaidis I, Panou F, Filippatos G, Kremastinos DT: Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil 2008;15:365–369.
36.
Palazzuoli A, Silverberg D, Iovine F, Capobianco S, Giannotti G, Calabrò A, Campagna SM, Nuti R: Erythropoietin improves anemia, exercise tolerance, and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 2006;152:1096.e9–e15.
37.
Palazzuoli A, Silverberg DS, Iovine F, Calabrò A, Campagna MS, Gallotta M, Nuti R: Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J 2007;154:645.e9–e15.
38.
Ponikowski P, Anker SD, Szachniewicz J, Okonko D, Ledwidge M, Zymlinski R, Ryan E, Wasserman SM, Baker N, Rosser D, Rosen SD, Poole-Wilson PA, Banasiak W, Coats AJ, McDonald K: Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2007;49:753–762.
39.
van Veldhuisen DJ, Dickstein K, Cohen-Solal A, Lok DJ, Wasserman SM, Baker N, Rosser D, Cleland JG, Ponikowski P: Randomized, double-blind placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. Eur Heart J 2007;28:2208–2216.
40.
Ghali J, Anand I, Abraham WT, Fonarow GC, Greenberg B, Krum H, Massie BM, Wasserman SM, Trotman ML, Sun Y, Knusel B, Armstrong P, Study of Anemia in Heart Failure Trial (STAMINA-HeFT) Group: Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. Circulation 2008;117:526–535.
41.
Abraham WT, Klapholz M, Anand I, Knusel B, Rosser D, Baker N, Sun Y, Van Veldhuisen DJ: Safety and efficacy of darbepoetin alfa treatment in anemic patients with symptomatic heart failure: a pooled analysis of two randomized, double-blind, placebo-controlled trials. Eur Heart J 2007;27(suppl):166.
42.
van der Meer P, Groenveld HF, Januzzi JL Jr, van Veldhuisen DJ: Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. Heart 2009;95:1309–1314.
43.
Abdulla J, Abildstrom SZ, Christensen E, Kober L, Torp-Pedersen C: A meta-analysis of the effect of angiotensin-converting enzyme inhibitors on functional capacity in patients with symptomatic left ventricular systolic dysfunction. Eur J Heart Fail 2004;6:927–935.
44.
MacMahon S, Sharpe N, Doughty R: Randomized placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet 1997;349:374–380.
45.
Klapholz M, Abraham WT, Ghali JK, Ponikowski P, Knusel B, Wasserman SM, Sun Y, Van Veldhuisen DJ: Pooled safety analysis of darbepoetin alfa in the treatment of symptomatic heart failure (abstract). Eur Heart J 2008;29(suppl):507.
46.
Naito Y, Tsujino T, Matsumoto M, Sakoda T, Ohyanagi M, Masuyama T: Adaptive response of the heart to long-term anemia induced by iron deficiency. Am J Physiol Heart Circ Physiol 2009;296:H585–H593.
47.
Dong F, Zhang X, Culver B, Chew HG, Kelley RO, Ren J: Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome C release: involvement of nitric oxide synthase and protein tyrosine nitration. Clin Sci (Lond)2005;109:277–286.
48.
Beutler E, Larsh SE, Gurney CW: Iron therapy in chronically fatigued, nonanemic women: a double-blind study. Ann Intern Med 1960;52:378–394.
49.
Beutler E: History of iron in medicine. Blood Cells Mol Dis 2002;29:297–308.
50.
Brownlie T, Untermohlen V, Hinton PS, Giordano C, Haas JD: Marginal iron deficiency without anemia impairs aerobic adaptation among previously untrained women. Am J Clin Nutr 2002;75:733–742.
51.
Verdon F, Burnand B, Stubi CL, Bonard C, Graff M, Michaud A, Bischoff T, de Vevey M, Studer JP, Herzig L, Chapuis C, Tissot J, Pécoud A, Favrat B: Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trial. BMJ 2003;326:1124–1126.
52.
Murphy CL, Fitzsimons EJ, Jardine AJ, Sattar N, Mcmurray JJV: Routine assessment of iron status in all patients with heart failure may identify those at risk of developing anemia. Eur J Heart Fail Suppl 2007;61:24.
53.
Grzeslo A, Jankowska EA, Witkowski T, Majda J, Petruk-Kowalczyk J, Banasiak W, Ponikowski P: Iron deficiency is a common finding in patients with stable chronic heart failure. Eur J Heart Fail Suppl 2006;5:132.
54.
Opasich C, Cazzola M, Scelsi L, De Feo S, Bosimini E, Lagioia R, Febo O, Ferrari R, Fucili A, Moratti R, Tramarin R, Tavazzi L: Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 2005;26:2232–2237.
55.
Nanas JN, Matsouka C, Karageorgopoulos D, Leonti A, Tsolakis E, Drakos SG, Tsagalou EP, Maroulidis GD, Alexopoulos GP, Kanakakis JE, Anastasiou-Nana MI: Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 2006;48:2485–2489.
56.
Bolger AP, Bartlett FR, Penston HS, O‘Leary J, Pollock N, Kaprielian R, Chapman CM: Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol 2006;48:1225–1227.
57.
Usmanov RI, Zueva EB, Silverberg DS, Shaked M: Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic renal insufficiency. J Nephrol 2008;21:236–242.
58.
Toblli J, Lombrana A, Duarte P, Di Gennaro F: Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol 2007;50:1657–1665.
59.
Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, Foldes G, Thum T, Majda J, Banasiak W, Missouris CG, Poole-Wilson PA, Anker SD, Ponikowski P: Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008;51:103–112.
60.
Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG: Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005;16:3070–3080.
61.
Feldman HI, Joffe M, Robinson B, Knauss J, Cizman B, Guo W, Franklin-Becker E, Faich G: Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004;15:1623–1632.
62.
Pollak VE, Lorch JA, Shukla R, Satwah S: The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data. BMC Nephrol 2009;10:6.
63.
Kovesdy CP, Estrada W, Ahmadzadeh S, Kalantar-Zadeh K: Association of markers of iron stores with outcomes in patients with nondialysis-dependent chronic kidney disease. Clin J Am Soc Nephrol 2009;4:435–441.
64.
Tuomainen TP, Punnonen K, Nyyssonen K, Salonen JT: Association between body iron stores and the risk of acute myocardial infarction in men. Circulation 1998;97:1461–1466.
65.
Sun Q, Ma J, Rifai N, Franco OH, Rexrode KM, Hu FB: Excessive body iron stores are not associated with risk of coronary heart disease in women. J Nutr 2008;138:2436–2441.
66.
Mircescu G, Garneata L, Capusa C, Ursea N: Intravenous iron supplementation for the treatment of anemia in predialyzed chronic renal failure patients. Nephrol Dial Transplant 2006;21:120–124.
67.
Gotloib L, Silverberg DS, Fudin R, Shostak A: Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol 2006;19:161–167.
68.
Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S, for the United States Iron Sucrose (Venofer) Clinical Trials Group: A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 2005;68:2846–2856.
69.
Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U: Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis Am J Kidney Dis 2008;52:897–906.
70.
Bishu K, Agarwal R: Acute injury with intravenous iron and concerns regarding long-term safety. Clin J Am Soc Nephrol 2006;1(suppl 1):S19–S23.
71.
Kuo KL, Hung SC, Wei YH, Tarng DC: Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients. J Am Soc Nephrol 2008;19:1817–1826.
72.
Darze ES, Latado AS, Guimarães AG, Guedes RA, Santos AB, de Moura SS, Passos LC: Incidence and clinical predictors of pulmonary embolism in severe heart failure patients admitted to a coronary care unit. Chest 2005;128:2576–2580.
73.
Imberti D, Pierfranseschi MG, Falciani M, Prisco D: Venous thromboembolism prevention in patients with heart failure: an often neglected issue. Pathophysiol Haemost Thromb 2008;36:69–74.
74.
Streja E, Kovesdy CP, Greenland S, Kopple JD, McAllister CJ, Nissenson AR, Kalantar-Zadeh K: Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 2008;52:727–736.
75.
Littlewood TJ: Normalization of hemoglobin in patients with CKD may cause harm: but what is the mechanism? Am J Kidney Dis 2008;52:642–644.
76.
Fishbane S: Erythropoiesis-stimulating agent treatment with full anemia correction: a new perspective. Kidney Int 2009;75:358–365.
77.
Dahl NV, Henry DH, Coyne DW: Thrombosis with erythropoietic stimulating agents – does iron-deficient erythropoiesis play a role? Semin Dial 2008;21:210–211.
78.
Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, Korbet S, Krantz SB, Lundin AP, Nissenson AR, Ogden DA, Paganini EP, Rader B, Rutsky EA, Stivelman J, Stone WJ, Teschan P, Van Stone JC, Van Wyck DB, Zuckerman K, Adamson JW: Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989;111:992–1000.
79.
Nagababu E, Gulyani S, Earley CJ, Cutler RG, Mattson MP, Rifkind JM: Iron-deficiency anaemia enhances red blood cell oxidative stress. Free Radic Res 2008;42:824–829.
80.
Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR, DRIVE Study Group: Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol 2007;18:975–984.
81.
Kapoian T, O’Mara NB, Singh AK, Moran J, Rizkala AR, Geronemus R, Kopelman RC, Dahl NV, Coyne DW: Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol 2008;19:372–379.
82.
Katodritou E, Zervas K, Terpos E, Brugnara C: Use of erythropoiesis stimulating agents and intravenous iron for cancer and treatment-related anaemia: the need for predictors and indicators of effectiveness has not abated. Br J Hematol 2008;142:3–10.
83.
Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, McKoy JM, Edwards BJ, Tigue CC, Raisch DW, Yarnold PR, Dorr DA, Kuzel TM, Tallman MS, Trifilio SM, West DP, Lai SY, Henke M: Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914–924.
84.
Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE: Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood 2008;111:25–41.
85.
Singh AK, Coyne DW, Shapiro W, Rizkala AR, DRIVE Study Group: Predictors of the response to treatment in anemic hemodialysis patients with elevated ferritin and low transferrin saturation. Kidney Int 2007;71:1163–1171.
86.
Fishbane S, Galgano C, Langley RC, Canfield W, Maesaka JK: Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int 1997;52:217–222.
87.
Maiese K, Li F, Chong ZZ: New avenues of exploration for erythropoietin. JAMA 2005;293:90–95.
88.
Arcasoy MO: The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008;141:14–31.
89.
Rastogi S, Sharov VG, Mishra S, Sabbah HN: Darbepoetin-alpha prevents progressive left ventricular dysfunction and remodeling in nonanemic dogs with heart failure. Am J Physiol Heart Circ Physiol 2008;295:H2475–H2482.
90.
Vaziri ND: Anemia and anemia correction: surrogate markers or causes of morbidity in chronic kidney disease. Nat Clin Pract Nephrol 2008;4:436–445.
91.
Krapf R, Hulter HN: Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA). Clin J Am Soc Nephrol 2009;4:470–480.
92.
US Food and Drug Administration: Information for Healthcare Professionals. Erythropoiesis Stimulating Agents (ESA). FDA Alert, 2007. http://www.fda.gov/cder/drug/InfoSheets/HCP/RHE200711HCP.htm
93.
Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085–2098.
94.
Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584–590.
95.
Phommintikul A, Haas HJ, Elsik M, Krum H: Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007;369:381–388.
96.
Pfeffer MA: Anemia treatment in chronic kidney disease: shifting uncertainty. Heart Failure Review 2008;13:425–430.
97.
Marketou M, Patrianakos A, Parthenakis F, Zacharis E, Arfanakis D, Kochiadakis G, Chlouverakis G, Vardas P: Systemic blood pressure profile in hypertensive patients with low hemoglobin concentrations. Int J Cardiol, E-pub ahead of print.
98.
Paul B, Wilfred NC, Woodman R, Depasquale C: Prevalence and correlates of anaemia in essential hypertension. Clin Exp Pharmacol Physiol 2008;35:1461–1464.
99.
Smilde TDJ, Damman K, van der Harst P, Navis G, Daan Westenbrink B, Voors AA, Boomsma F, van Veldhuisen DJ, Hillege HL: Differential associations between renal function and ‘modifiable’ risk factors in patients with chronic heart failure. Clin Res Cardiol 2009;98:121–129.
100.
Logeart D, Gueffet JP, Rouzet F, Pousset F, Chavelas C, Solal AC, Jondeau G: Heart rate per se impacts cardiac function in patients with systolic heart failure and pacing: a pilot study. Eur J Heart Fail 2009;11:53–57.
101.
Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez Sendon JL, Steg PG, Tardif JC, Tavazzi L, Tendera M, Heart Rate Working Group: Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007;50:823–830.
102.
Vaisman N, Silverberg DS, Wexler D, Niv E, Blum M, Keren G, Soroka N, Iaina A: Correction of anemia in patients with congestive heart failure increases resting energy expenditure. Clin Nutr 2004;23:355–361.
103.
Levy PS, Kim SJ, Eckel PK, Chavez R, Ismail EF, Gould SA, Ramez Salem M, Crystal GJ: Limit to cardiac compensation during acute isovolemic hemodilution: influence of coronary stenosis. Am J Physiol 1993;265:H340–H349.
104.
Collins AJ, Guo H, Gilbertson DT, Bradbury BD: Predictors of ESA use in the non-dialysis chronic kidney disease population with anemia. Nephron Clin Pract 2009;111:c141–c148.
105.
Tang WH, Tong W, Jain A, Francis GS, Harris CM, Young JB: Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic renal failure. J Am Coll Cardiol 2008;51:569–576.
106.
Nissenson AR, Wade S, Goodnough T, Knight K, Dubois RW: Economic burden of anemia in an insured population. J Manag Care Pharm 2005;11:565–574.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.